Relationship between risk stratification at admission and treatment effects of early invasive management following fibrinolysis: insights from the Trial of Routine ANgioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI)
Open Access
- 8 February 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 32 (16), 1994-2002
- https://doi.org/10.1093/eurheartj/ehr008
Abstract
We sought to determine the effectiveness of early routine percutaneous coronary intervention (PCI) post-fibrinolysis for ST-elevation myocardial infarction (STEMI) in relation to baseline risk status. In this post hoc subgroup analysis of Trial of Routine Angioplasty and Stenting after Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI), we stratified 1059 STEMI patients receiving tenecteplase into low-intermediate [Global Registry of Acute Coronary Events (GRACE) risk score n = 889] vs. high-risk (GRACE risk score ≥155; n = 170) groups, based on the GRACE risk score for in-hospital mortality. There was a significant interaction between treatment assignment and risk status for the composite endpoint of death/re-MI at 30 days (P for interaction P < 0.001), but a higher rate of death/re-MI in the high-risk group (13.8 vs. 27.8%, P = 0.025). We found similar heterogeneity in the treatment effects on 30-day mortality and death/re-MI at 1 year (P for interaction =0.008 and 0.001, respectively), when the GRACE risk score was analysed as a continuous variable (P for interaction P for interaction = 0.001). We observed a strong heterogeneity in the treatment effects of a pharmacoinvasive strategy after fibrinolysis for STEMI, which is associated with improved outcomes only among patients with a low-intermediate GRACE risk score. Conversely, the early invasive strategy is associated with worse outcomes in high-risk patients. These novel findings should be considered exploratory only and require confirmation in other trials and meta-analyses. Clinical Trial Registration Information: http://www.clinicaltrials.gov/ct2/show/NCT00164190 ClinicalTrials.gov number, NCT00164190Keywords
This publication has 44 references indexed in Scilit:
- Management of acute myocardial infarction in patients presenting with persistent ST-segment elevationEuropean Heart Journal, 2008
- Commentary: The Role of Percutaneous Coronary Intervention in ST-Segment–Elevation Myocardial InfarctionCirculation, 2008
- Angioplasty Strategies in ST-Segment–Elevation Myocardial InfarctionCirculation, 2008
- Comparison of Thrombolysis Followed by Broad Use of Percutaneous Coronary Intervention With Primary Percutaneous Coronary Intervention for ST-Segment–Elevation Acute Myocardial InfarctionCirculation, 2008
- 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial InfarctionCirculation, 2008
- A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) studyEuropean Heart Journal, 2006
- Combined Angioplasty and Pharmacological Intervention Versus Thrombolysis Alone in Acute Myocardial Infarction (CAPITAL AMI Study)Journal of the American College of Cardiology, 2005
- Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trialThe Lancet, 2004
- Beneficial effects of immediate stenting after thrombolysis in acute myocardial infarctionJournal of the American College of Cardiology, 2003
- Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trialsThe Lancet, 2003